2025
Dendritic cell phagosomes recruit GRASP55 for export of antigen-loaded MHC molecules
Cebrian I, Dinamarca S, Rodríguez M, Priego E, Brouwers N, Barends M, Brunnberg J, Tampé R, Blanchard N, Sancho D, Malhotra V. Dendritic cell phagosomes recruit GRASP55 for export of antigen-loaded MHC molecules. Cell Reports 2025, 44: 115333. PMID: 39955774, PMCID: PMC11861518, DOI: 10.1016/j.celrep.2025.115333.Peer-Reviewed Original ResearchConceptsExogenous antigen presentationDendritic cellsAntigen presentationMHC moleculesBone marrow-derived dendritic cellsBone marrow-derived DCCD4<sup>+</sup> T cellsMHC-IActivated CD8<sup>+</sup>MHC class IIDendritic cell phagosomesMHC II moleculesCD8<sup>+</sup>Peptide-loaded MHC moleculesT cellsExogenous antigensMHC-IIClass IIAntigenEndocytic systemGRASP55Cell surfaceIntracellular transportPlasma membranePresentation
2024
PP7.9 – 00031 Memory B Cells in the CSF of People with HIV Exhibit Changes in Interferon Signaling and Antigen Presentation Capacity
Filippidis P, Corley M, Spudich S, Wang M, Kleinstein S, Farhadian S. PP7.9 – 00031 Memory B Cells in the CSF of People with HIV Exhibit Changes in Interferon Signaling and Antigen Presentation Capacity. Journal Of Virus Eradication 2024, 10: 89-90. DOI: 10.1016/j.jve.2024.100532.Peer-Reviewed Original ResearchMachine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines
Kovalchik K, Hamelin D, Kubiniok P, Bourdin B, Mostefai F, Poujol R, Paré B, Simpson S, Sidney J, Bonneil É, Courcelles M, Saini S, Shahbazy M, Kapoor S, Rajesh V, Weitzen M, Grenier J, Gharsallaoui B, Maréchal L, Wu Z, Savoie C, Sette A, Thibault P, Sirois I, Smith M, Decaluwe H, Hussin J, Lavallée-Adam M, Caron E. Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines. Nature Communications 2024, 15: 10316. PMID: 39609459, PMCID: PMC11604954, DOI: 10.1038/s41467-024-54734-9.Peer-Reviewed Original ResearchConceptsT cell epitopesT cellsCD8+ T cell epitopesT cell immunityT cell epitope discoverySARS-CoV-2T-cell-directed vaccinationDesigning effective vaccinesB7 supertypePatient's proteomesSARS-CoV-2 variantsVaccine epitopesViral antigensSpike antigenVaccine developmentEffective vaccineEpitope discoveryCOVID-19 vaccineVaccineEpitopesAntigenic featuresOmicron variantAntigenCOVID-19CD8Targeting T-Cell Costimulation to the Surface of Tumor Cells.
Eguren-Santamaría I, Sanmamed M, Molero-Glez P, Perez-Gracia J, Melero I. Targeting T-Cell Costimulation to the Surface of Tumor Cells. Clinical Cancer Research 2024, 31: 231-233. PMID: 39531541, DOI: 10.1158/1078-0432.ccr-24-3003.Peer-Reviewed Original ResearchT lymphocytesTumor cellsTargeting T-cell costimulationSurface of tumor cellsT cell costimulationProportion of patientsT cell activationAntitumor responseT cellsSolid tumorsSurface antigensActivator receptorSignal 2CostimulationTumorTarget specificityCellsCD137HER2Novel evidencePatientsAntigenReceptorsLactate fermentation intoxicates TILs
Hunt B, Kessler E, Joshi N. Lactate fermentation intoxicates TILs. Nature Immunology 2024, 25: 2176-2177. PMID: 39516647, DOI: 10.1038/s41590-024-02020-7.Peer-Reviewed Original ResearchSpatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, Yang C, Yang Y, Song Y. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants. Angewandte Chemie International Edition 2024, 63: e202412294. PMID: 39030890, DOI: 10.1002/anie.202412294.Peer-Reviewed Original ResearchNanoparticle vaccineReceptor-binding domainHeterotypic antigensBroad-spectrum neutralizing antibodiesSARS-CoV-2 spike trimerVaccine-induced immunityNanotechnology-based strategiesEnhanced immune activationOmicron receptor-binding domainMosaic vaccinesImmune activationSystematic in vitroNeutralizing antibodiesSARS-CoV-2 variantsMosaic nanoparticlesImmunological investigationsExcessive inflammationAntigen distributionAntigenSpike trimerRBD antigenSARS-CoV-2DNAVaccineAntiviral capabilitiesSpatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, Yang C, Yang Y, Song Y. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants. Angewandte Chemie 2024, 136 DOI: 10.1002/ange.202412294.Peer-Reviewed Original ResearchNanoparticle vaccineReceptor-binding domainHeterotypic antigensBroad-spectrum neutralizing antibodiesSARS-CoV-2 spike trimerVaccine-induced immunityNanotechnology-based strategiesEnhanced immune activationOmicron receptor-binding domainMosaic vaccinesImmune activationSystematic in vitroNeutralizing antibodiesSARS-CoV-2 variantsMosaic nanoparticlesImmunological investigationsExcessive inflammationAntigen distributionAntigenSpike trimerRBD antigenSARS-CoV-2DNAVaccineAntiviral capabilitiesScaleable production of highly loaded protein nanoparticles for immune modulation
Caplan M, Baldwin R, Yin X, Grishin A, Eisenbarth S, Sampson H, Bottomly K, Prud’homme R. Scaleable production of highly loaded protein nanoparticles for immune modulation. Communications Materials 2024, 5: 191. DOI: 10.1038/s43246-024-00626-w.Peer-Reviewed Original ResearchAdjuvants to antigen-presenting cellsImmune modulationAntigen-presenting cellsMurine immune systemImmune system cellsPeanut-allergic patientsDesensitizer applicationPLG nanoparticlesAntigen deliverySystemic exposurePoly(lactide-co-glycolideBasophil activationClinical investigationAllergic responsesImmune systemSystem cellsProtein antigensClinical applicationDelivery of proteinsE. coli phospholipidsSafety evidenceAntigenProtein nanoparticlesDeliveryCellsExploring new perspectives in immunology
Medzhitov R, Iwasaki A. Exploring new perspectives in immunology. Cell 2024, 187: 2079-2094. PMID: 38670066, DOI: 10.1016/j.cell.2024.03.038.Peer-Reviewed Original ResearchImmunoglobulins; Fundamentals and Their Role in Neurological Disease
Khani-Habibabadi F, O’Connor K. Immunoglobulins; Fundamentals and Their Role in Neurological Disease. 2024 DOI: 10.1016/b978-0-323-95702-1.00066-x.Peer-Reviewed Original Research
2023
Bacterial antigens unleash tumor-targeting immunity
Boeck N, Trajanoski Z, Galluzzi L. Bacterial antigens unleash tumor-targeting immunity. Cell Host & Microbe 2023, 31: 1945-1947. PMID: 38096784, PMCID: PMC11075005, DOI: 10.1016/j.chom.2023.11.001.Peer-Reviewed Original ResearchCancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Vylegzhanina A, Bespalov I, Novototskaya-Vlasova K, Hall B, Gleiberman A, Yu H, Leontieva O, Leonova K, Kurnasov O, Osterman A, Dy G, Komissarov A, Vasilieva E, Gehlhausen J, Iwasaki A, Ambrosone C, Tsuji T, Matsuzaki J, Odunsi K, Andrianova E, Gudkov A. Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans. Cancer Research Communications 2023, 3: 2256-2267. PMID: 37870410, PMCID: PMC10631453, DOI: 10.1158/2767-9764.crc-23-0289.Peer-Reviewed Original ResearchConceptsL1 antigenCancer typesDisease stage 1Discovery of autoantibodiesHigh IgG titersTumor-associated antigensDetermination of immunoreactivityTumor immunoreactivityCirculating AntibodiesIgG titersAntibody responseImmune responseLiver cancerReactive IgGHealthy individualsCurable cancer typesImmune systemAntigenNormal tissuesPatientsCancerEarly detectionElevated levelsCarcinogenic processAutoantibodiesAntibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression
Jajosky R, Patel K, Allen J, Zerra P, Chonat S, Ayona D, Maier C, Morais D, Wu S, Luckey C, Eisenbarth S, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood 2023, 142: 1082-1098. PMID: 37363865, PMCID: PMC10541552, DOI: 10.1182/blood.2022018591.Peer-Reviewed Original ResearchConceptsAntibody-mediated immunosuppressionRBC alloantigensImmune responseFetal red blood cell antigensTarget antigenRed blood cell antigensRh immune globulinMaternal immune responseBlood cell antigensInclusion of antibodiesRBC removalAnti-RhD antibodiesAbility of antibodiesImmune globulinAntibody responseHemolytic diseaseRBC clearanceCell antigensFetal RBCsAntibody characteristicsAlloantigensSimilar interventionsAntibodiesAntigenPolyclonal antibody preparationCancer- and infection-induced T cell exhaustion are distinct
Buck J, Joshi N. Cancer- and infection-induced T cell exhaustion are distinct. Nature Immunology 2023, 24: 1604-1605. PMID: 37709988, DOI: 10.1038/s41590-023-01624-9.Peer-Reviewed Original ResearchConvergent evolution and B-cell recirculation in germinal centers in a human lymph node
Pelissier A, Stratigopoulou M, Donner N, Dimitriadis E, Bende R, Guikema J, Martinez M, van Noesel C. Convergent evolution and B-cell recirculation in germinal centers in a human lymph node. Life Science Alliance 2023, 6: e202301959. PMID: 37640448, PMCID: PMC10462906, DOI: 10.26508/lsa.202301959.Peer-Reviewed Original ResearchConceptsGerminal centersLymph nodesHuman lymph nodesGC responseHuman LNImmune responseDevelopment of autoimmune diseasesConvergent evolutionB cell clonesB cell recirculationEffective immune responseExpanded clonesLaser capture microdissectionPhylogenetic tree analysisIndividual germinal centersB cellsAutoimmune diseasesAntigen responseMouse modelModel antigenAntigenClonal diversityFingertip ischemia following intralesional injection of <i>Candida albicans</i> antigen for treatment of a subungual wart
Evans B, Newman-Plotnick H, Prsic A. Fingertip ischemia following intralesional injection of Candida albicans antigen for treatment of a subungual wart. Dermatology Reports 2023, 16: 9748. PMID: 38585492, PMCID: PMC10993649, DOI: 10.4081/dr.2023.9748.Peer-Reviewed Original ResearchSoft tissue necrosisCandida albicans antigenIntralesional injectionSubungual wartsHuman papillomavirusTissue necrosisLocal wound careSoft tissue ischemiaSoft tissue reconstructionEmergent revascularizationIntralesional immunotherapyDestructive therapyDigital ischemiaCutaneous wartsCase reportHand surgeonsTissue ischemiaWound careIschemiaDigital vesselsDigital vasculatureWartsAntigenTissue reconstructionInjectionAntigenic targets in clear cell renal cell carcinoma
Schindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRenal cell carcinomaImmune checkpoint inhibitorsCell carcinomaImmune-related adverse effectsEffective anti-tumor immunityAdvanced renal cell carcinomaClear cell renal cell carcinomaAntigen-directed immunotherapySafety of immunotherapyClear cell histologyAnti-tumor immunityCell renal cell carcinomaCheckpoint inhibitorsCell histologyICI responseMost patientsNeoantigen loadCurrent therapiesAntigenic targetsLong-term benefitsMutation burdenTarget antigenAdverse effectsAntigenImmunotherapySearch of a genomic sequence database for potential novel blood group antigens: Investigation into why some amino acid substitutions are not immunogenic
Howe J, Stack G. Search of a genomic sequence database for potential novel blood group antigens: Investigation into why some amino acid substitutions are not immunogenic. Transfusion 2023, 63: 1399-1411. PMID: 37386886, DOI: 10.1111/trf.17459.Peer-Reviewed Original ResearchConceptsBlood group antigensGroup antigensB-cell epitopesGenomic sequence databasesLinear B-cell epitopesLow prevalenceSequence databasesAtypical chemokine receptor 1Chemokine receptor 1New blood group antigensExtracellular domainHuman genome sequence databaseMissense mutationsGenome sequence databaseEpitope prediction programsTransfusion practiceProtein structural analysisPoor immunogenicityAmino acid substitutionsReceptor 1Phenotype prevalenceAntigenStudy designBlood groupPrevalenceOptimization of a high-throughput shotgun immunoproteomics pipeline for antigen identification
Shortreed N, Panicker A, Mangalaparthi K, Zhong J, Pandey A, Griffiths L. Optimization of a high-throughput shotgun immunoproteomics pipeline for antigen identification. Journal Of Proteomics 2023, 281: 104906. PMID: 37059220, PMCID: PMC10399726, DOI: 10.1016/j.jprot.2023.104906.Peer-Reviewed Original ResearchConceptsAdaptive immune responsesImmune responseAntigen identificationPreparation of protein extractsProtein extractsIdentification of proteinsImmunoproteomic approachAffinity chromatography columnIntra-experimental variabilityTrifluoroacetic acidPre-clinicalUnique antigensDisruption methodsTMT labelingLC-MS/MSHypothesis-driven approachIncreased total numberAntigenLC-MS/MS analysisAntigenic proteinsMass spectrometry timeProteinHigh-throughputLongitudinal mannerImmunoprecipitationHemolytic disease of the fetus and newborn mediated by anti-Dia in a U.S. hospital
Jacobs J, Abels E, Binns T, Tormey C, Sostin N. Hemolytic disease of the fetus and newborn mediated by anti-Dia in a U.S. hospital. Immunohematology 2023, 39: 32-34. PMID: 37017601, DOI: 10.21307/immunohematology-2023-006.Peer-Reviewed Case Reports and Technical NotesConceptsHemolytic diseaseCases of HDFNU.S. hospitalsHemolytic transfusion reactionsDirect antiglobulin testNeonatal bilirubin levelsSouth American descentAntibody detection testsLow-prevalence antigensU.S. patient populationNear universal absenceHDFN casesBilirubin levelsPatient populationTransfusion reactionsAntiglobulin testUnexpected causeHispanic ethnicityBlood group systemAntigenAntibodiesHDFNHospitalFetusesDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply